Business
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS a
About this update from Elicio Therapeutics, Inc.
[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dHRdNHTDYzkn3cTM5JZhnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":329,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":188,"olType":false},{"type":"text","content":"BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ended December 31, 2025, and provided recent corporate and clinical updates.","length":349,"tagName":"p"},{"type":"text","content":"“In 2025, we made meaningful progress advancing ELI-002 7P in KRAS-mutant pancreatic cancer,” said Robert Connelly, Chief Executive Officer of Elicio. “We remain focused on completing the Phase 2 AMPLIFY-7P trial and reaching the event-driven primary DFS analysis expected in 1H 2026. We are encouraged by the continued observation of fewer disease progressions and deaths to date than projected in the 2:1 randomized trial, as well as by the durability of T-cell res...